Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed ...

An update from Novavax ( (NVAX)) is now available. At its June 18, 2026 annual meeting, Novavax stockholders elected Class I directors John C. Jacobs, Gregg H. Alton and Richard J. Rodgers to ...

Novavax (NVAX Quick Quote NVAX - Free Report) is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.

Novavax has transferred commercialization of its COVID-19 vaccine in Europe to Sanofi. The company is shifting focus to monetizing its Matrix-M adjuvant through partnerships and licensing. These moves ...

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Good morning and welcome to Novavax Fourth Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company said Wednesday. The update sent Novavax's stock up more than 21% in early ...

WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty ...